Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Healthia has entered binding agreements to acquire nine more health clinics around Australia
  • The clinics include: three physiotherapy in Queensland and six podiatry clinics in Queensland and Victoria
  • The nine new health clinics will cost Healthia $5.620 million

Healthia Limited has entered binding agreements to acquire nine more health clinics around Australia.

The health clinics include: three physiotherapy clinics in Queensland, three podiatry clinics in Queensland and three podiatry clinics in Victoria.

Healthia is an integrated group of health-based companies, who aim to help people in health services. Healthia has allied businesses such as My FoorDr, Allsports Physiotherapy, Extend Rehabilitation, iOrthotics and D.B.S. Medical Supplies.

Financial and property leases will have to be approved and settlement is expected to be by August 31.

These nine new health clinics will cost Healthia $5.620 million and are expected to bring in $6.717 million.

CEO, Wes Coote is happy with the acquisitions of the new health clinics and is excited for what the rest of the year holds.

“We are pleased with the partnership we have been able to make with new clinics throughout FY19 and happy with the momentum we are gaining moving into FY20,” he said.

HLA by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.